^
    6ms
    Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov)
    P1, N=121, Active, not recruiting, Incyte Corporation | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    itacitinib (INCB039110) • dezapelisib (INCB040093)
    10ms
    Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov)
    P1, N=121, Active, not recruiting, Incyte Corporation | Trial completion date: Jan 2025 --> Apr 2025 | Trial primary completion date: Jan 2025 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    itacitinib (INCB039110) • dezapelisib (INCB040093)
    1year
    Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov)
    P1, N=121, Active, not recruiting, Incyte Corporation | Trial completion date: Aug 2024 --> Jan 2025 | Trial primary completion date: Aug 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    |
    itacitinib (INCB039110) • dezapelisib (INCB040093)
    over1year
    Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov)
    P1, N=121, Active, not recruiting, Incyte Corporation | Trial completion date: Feb 2024 --> Aug 2024 | Trial primary completion date: Feb 2024 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    itacitinib (INCB039110) • dezapelisib (INCB040093)
    over2years
    Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies (clinicaltrials.gov)
    P1, N=121, Active, not recruiting, Incyte Corporation | Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
    Trial completion date • Trial primary completion date
    |
    itacitinib (INCB039110) • dezapelisib (INCB040093)